We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-14.00 | -0.12% | 12,096.00 | 12,086.00 | 12,092.00 | 12,118.00 | 12,038.00 | 12,090.00 | 1,525,268 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.47 | 187.42B |
Date | Subject | Author | Discuss |
---|---|---|---|
05/1/2021 01:45 | Where a share was has no bearing on where it is now! | freddie ferret | |
04/1/2021 23:31 | GSK down from £18 to £14 in 12 months. AZN down from £76 to £74 in the same period. I think we have a winner. :-) | davius | |
04/1/2021 23:07 | That's true Monty - there's always bulls and bears. But this share was nearly £100 not so long ago and if you really are shorting that's the thing to bear in mind. But I do agree you with you on the potential for GSK to do really well this year | mercury123 | |
04/1/2021 23:02 | Down from 8200p in 4 weeks, some traders thinking the same has me. That's what makes a market bulls and bears. | montyhedge | |
04/1/2021 22:50 | Mercury123, I agree very risky! Monty has declared his short position, although I doubt he ever trades but I wish he'd take his drivel elsewhere. Doubt he'd like it if some AZN BB holders started negative GSK BB comments. Seems he hasn't anything better to do. | beckers2008 | |
04/1/2021 18:53 | I wouldn't be short monty - too risky. Fine not being long but really risky being short | mercury123 | |
04/1/2021 18:12 | Can't see how you can be short on this share. ESP when there are so many better candidates at the mo | bogman1 | |
04/1/2021 18:01 | Who knows the story of the chicken and pig. One day the chicken says to the pig, eggs and bacon selling well for breakfast, let's merge, great said the pig. We will make a fortune says the chicken. Then the pig thought about it, but chicken you just lay eggs everyday, I get carved up for the bacon.Chicken says that's why a called it a merger and not a takeover. | montyhedge | |
04/1/2021 17:57 | What I see 45% premium, ok got to pay up, they may have to pay more we will see. Paying part cash, that's ok can borrow the money, but seems they will have 15% of Astra, two seats on the board. Now that would be ok for a bid say a big pharma company.Surely not a smaller company, seems more of a merger. In the long run if all works out great, but short term I don't know.Problem for me long GSK, short Astra, they act in pairs, one goes up they both go up, go down they seem to both go down, lol. | montyhedge | |
04/1/2021 16:58 | Thanks Beckers, not very often I agree with Motley, on pretty much anything. But this bit looks spot on: AstraZeneca raised a lot of eyebrows recently with an offer to acquire Alexion Pharmaceuticals (NASDAQ:ALXN) for $39 billion in a combination of cash and AstraZeneca stock. This deal probably won't close until the second half of 2021, but AstraZeneca will gain the Soliris/Ultomiris franchise when it does. Soliris is a complement inhibitor launched in 2007 to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder that causes some patients' immune systems to attack healthy blood cells. Over the years, Alexion funneled a lot of Soliris profits into expanding its addressable patient population and succeeded. At its current growth rate, Soliris franchise sales will reach $6 billion next year. In 2018, Alexion successfully launched a longer-lasting version of its lead drug called Ultomiris, which requires a maintenance dose delivered through intravenous infusion every other month. While less expensive biosimilar versions of Soliris could become available several years from now, its maintenance dose needs to be infused every other week. A drug that doesn't stick around at therapeutic concentrations very long isn't just an annoyance, there's increased potential for treatment gaps when people need to reschedule appointments. As a big pharma with more resources than Alexion had to work with, AstraZeneca could squeeze decades of healthy returns from its acquisition of Alexion. | davius | |
04/1/2021 16:47 | You don't say! | beckers2008 | |
04/1/2021 15:05 | Lol, I'm short you idiot. | montyhedge | |
04/1/2021 14:57 | Montyhedge, Leave this BB and stick to the BB's that you have holdings, if you have any? | beckers2008 | |
04/1/2021 14:34 | Not the vaccine that will push Astra higher, great for mankind, but no great profits from it.It's the bid, deal won't be closed until 3rd quarter this year. So in the meantime a lot of movement up and down on the bid on news, are they paying to much, dilution, etc. | montyhedge | |
04/1/2021 08:11 | Being televised now first person getting vaccine at Oxford Hospital, game changer, market is up on the news | triple witcher | |
03/1/2021 14:10 | 4 Reasons to Buy AstraZeneca Stock Now | The Motley Fool For the Fool, this is a reasonable write up; hxxps://www.fool.com | beckers2008 | |
03/1/2021 12:55 | azn vaccine approved for roll out in India. Its low cost and fridge temp storage will ensure its a winner. | coxsmn | |
03/1/2021 00:00 | Well AZN got a New year Tip in the Friday Daily Telegraph for what its worth! | mercury123 | |
02/1/2021 23:24 | That is now out of date since they are only using one jab. | freddie ferret | |
02/1/2021 23:10 | Vaccine priority list: | bountyhunter | |
02/1/2021 16:02 | Montyhedge, Do shares really go up and down? Well thanks for the advice, that's where I have been going wrong. | turvart | |
01/1/2021 13:22 | Montyhedge, Leave this BB and stick to the BB's that you have holdings, if you have any? | beckers2008 | |
01/1/2021 13:18 | Like I said shares go up and down, stop crying because Astra gone down, they will eventually go back up. | montyhedge | |
01/1/2021 12:03 | Montyhedge, Leave this BB and stick to the BB's that you have holdings, if you have any? | beckers2008 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions